Non-Small Cell Lung Cancer Coverage from Every Angle

Nivolumab in the First-Line Treatment of Advanced or Recurrent Lung Cancer

Based on the findings of the phase III CheckMate 026 trial, first-line nivolumab offered no progression-free survival benefit over platinum-based chemotherapy in patients with stage IV or recurrent non–small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) expression level ≥ 5%. However, David P. Carbone, MD, PhD, Director, James Thoracic Center, The Ohio State University Comprehensive Cancer Center, and colleagues reported nivolumab had a favorable safety profile compared with chemotherapy, and overall survival was similar between the groups, in an article in The New England Journal of Medicine.

A total of 541 patients with PD-L1 tumor expression ≥ 1% were included in this open-label international trial. Approximately half received nivolumab every 2 weeks, and the other half received investigator’s choice of platinum doublet chemotherapy every 3 weeks for 4 to 6 cycles. Chemotherapy regimens consisted of pemetrexed/carboplatin, pemetrexed/cisplatin, gemcitabine/carboplatin, gemcitabine/cisplatin, and paclitaxel/carboplatin.

Of the 423 patients with PD-L1 expression level ≥ 5%, the median progression-free survival was 4.2 months with nivolumab versus 5.9 months with chemotherapy. The median overall survival was 14.4 months with nivolumab versus 13.2 months with chemotherapy. Treatment-related adverse events of any grade were more common with chemotherapy than with nivolumab (92% vs. 71%), as were treatment-related grade 3 or 4 adverse events (51% vs. 18%).

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.